BTG-K BlendAlso known as: BPC-157/TB-500/GHK-Cu/KPV, BPC-157, Thymosin Beta-4, GHK-Cu, KPV

Mechanism of Action

The BTG-K Blend combines the distinct mechanisms of four peptides: BPC-157 promotes tissue repair primarily via VEGF-mediated angiogenesis enhancing vascular growth and regeneration; TB-500 (Thymosin Beta-4) facilitates cell migration and angiogenesis by modulating actin cytoskeleton dynamics, promoting cellular movement and repair; GHK-Cu (Copper peptide) stimulates collagen synthesis and exhibits potent antioxidant activity, contributing to skin remodeling and healing; and KPV modulates inflammatory responses by cytokine regulation resulting in reduced pro-inflammatory signaling. The combined action results in synergistic enhancement of tissue regeneration, neuroprotection, inflammation reduction, and skin renewal.

Reported Research Benefits

Primarily used in preclinical research for promoting muscle repair, wound healing, angiogenesis, anti-aging interventions, neuroregeneration, collagen stimulation for skin health, and immune modulation. It is studied as a regenerative and anti-inflammatory agent in dermatology, neurology, and immunology research contexts.

Dosing Protocol & Reconstitution

Typically prepared by reconstituting the lyophilized peptides in bacteriostatic water. In research, administered subcutaneously using precise dosing calibrated by peptide calculators, frequently with insulin syringes. Storage of reconstituted solutions at 2–8°C with stability up to 60 days is advised. Exact dosing depends on experimental design and concentration but generally involves low microgram to milligram doses per administration in laboratory models.

Research Notes

Research indicates that this peptide blend enhances tissue regeneration and immune modulation in animal and in vitro models. The blend is noted for its potential to accelerate tendon and ligament healing, stimulate collagen production, and reduce inflammation without addictive properties or known severe toxicities. Efficacy relies on controlled experimental conditions, and clinical data in humans are lacking as the blend is intended strictly for research.

Research Summary

BTG-K adds KPV's targeted anti-inflammatory action to the BPC-157/TB-500/GHK-Cu foundation. The addition of KPV makes this blend particularly suited for recovery protocols involving gut health or systemic inflammation, as KPV is one of the most potent natural inhibitors of intestinal NF-κB activation.

Side Effects & Safety

No documented serious adverse events across component peptides in animal models. Human trial data absent for this combination. Use with standard precautions for research peptides.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, TB-500 (Thymosin Beta-4): Ac-Ser-Asp-Lys-Pro-Val-Thr-Thr-Lys-Asp-Ser-Glu-Ile-Gln-Ala-Val-Ser-Lys-Ser-Leu-Glu-Lys-Phe-Thr-Thr-Lys-Asp-Lys-Val-Lys-Glu-Lys-Gln-Gln-Val-Val-Glu, GHK-Cu: Gly-His-Lys (Copper peptide complex), KPV: Lys-Pro-Val

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+KPV+anti-inflammatory+peptide